Stock COCP COCRYSTAL PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Cocrystal Pharma, Inc.

Equities

COCP

US19188J4094

Delayed Nasdaq
Other stock markets
 15:59:13 03/05/2024 BST 		5-day change 1st Jan Change
1.601 USD +0.70% Intraday chart for Cocrystal Pharma, Inc. +2.97% -7.03%
05-01 Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects CI
03-28 Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects
Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates
Top Premarket Gainers
Cocrystal Pharma, Inc. Announces First-Patient-In for Phase 2A Human Challenge Study Evaluating Oral Cc-42344 in Pandemic and Seasonal Influenza A
Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast
Cocrystal Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Cocrystal Pharma, Inc. Doses First Subjects in Clinical Study of CDI-988 for Pandemic Norovirus and Coronavirus
Cocrystal Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Cocrystal Pharma Files $150 Million Mixed Shelf
Cocrystal Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Cocrystal Pharma Files $150 Million Mixed Shelf
Cocrystal Pharma, Inc. Appoints Fred Hassan to Its Board of Directors
Insider Buy: Cocrystal Pharma
Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Cocrystal Pharma Says Study of Antiviral Treatment for Influenza A Showed Mild Adverse Events
Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
CoCrystal Pharma, Inc. Highlights Progress with CC-42344 as Potential Oral Treatment for Pandemic and Seasonal Influenza A at World Antiviral Congress 2022
Cocrystal Pharma, Inc. Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
Cocrystal Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. COCP Stock
  4. News Cocrystal Pharma, Inc.
  5. Other languages